Form 4: Amicus Therapeutics Acquired by BioMarin

Director Glenn Sblendorio reports the disposal of all equity holdings following the acquisition of Amicus Therapeutics by BioMarin Pharmaceutical Inc.

Summary

• Director Glenn Sblendorio disposed of 142,564 shares of common stock at a price of $14.50 per share.
• Multiple tranches of stock options totaling 303,630 shares were cancelled and converted into cash payments based on the $14.50 merger price.
• The transactions were executed on April 27, 2026, in connection with the completed acquisition of Amicus Therapeutics (FOLD) by BioMarin Pharmaceutical Inc.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative filing documenting the final exit of a director following a completed corporate acquisition.

Positives

• The acquisition price of $14.50 per share provided liquidity for the director's equity holdings.
• All outstanding stock options held by the director were fully vested and converted into cash consideration.

Negatives

• The director no longer holds any equity interest in Amicus Therapeutics following the completion of the merger.

Risks

• The company has been acquired and is no longer an independent publicly traded entity.

Future Outlook

The company has been acquired by BioMarin Pharmaceutical Inc., and as such, no further independent forward-looking guidance is provided.

Management Comments

• The reported securities were disposed of in connection with the consummation of the acquisition of the Issuer by BioMarin Pharmaceutical Inc.

Industry Context

StockSavvy.ai notes that this filing confirms the finalization of a significant M&A event in the biopharmaceutical sector, reflecting ongoing consolidation trends where larger players acquire specialized firms to bolster their pipelines.

Comparison to Industry Standards

• The acquisition of Amicus Therapeutics aligns with standard industry practices for mid-cap biotech exits via cash-out mergers.
• The conversion of unvested equity and options into cash upon a change-in-control is a standard provision in executive compensation agreements.

Stakeholder Impact

• Shareholders have received the merger consideration of $14.50 per share.
• The company is now a subsidiary of BioMarin Pharmaceutical Inc.

Next Steps

• Delisting of Amicus Therapeutics (FOLD) from public exchanges.

Key Dates

Keywords

Amicus Therapeutics, BioMarin, Merger, Acquisition, FOLD, Form 4, Insider Transaction